A Novel Genetically Modified Oncolytic Vaccinia Virus in Experimental Models is Effective Against a Wide Range of Human Cancers

Background Replication-competent oncolytic viruses have shown great promise as a potential cancer treatment. This study aimed to determine whether a novel vaccinia virus, GLV-1h151, with genetic modifications enhancing cancer specificity and enabling virus detection, is effective against a range of human cancers and is safe when administered in preclinical models.